Search Results - "Ghelardi, F." :: K.UTB vyhledávací portál

Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset

by Germani, M.M., Vetere, G., Santamaria, F., Intini, R., Ghelardi, F., Bensi, M., Boccaccino, A., Minelli, A., Carullo, M., Ciracì, P., Passardi, A., Santucci, S., Giampieri, R., Persano, M., Fenocchio, E., Puccini, A., Lonardi, S., Pietrantonio, F., Salvatore, L., Cremolini, C.
Published in ESMO open (01.04.2024)

Get full text

Journal Article

Loading…

$641P Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)$

641P Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)

by Pietrantonio, F., Morano, F., Niger, M., Ghelardi, F., Chiodoni, C., Palazzo, M., Brambilla, N., Benincasa, E., Giacovelli, G., Vitalini, C., Girolami, F., Rovati, L.C.
Published in Annals of oncology (01.10.2023)

Get full text

Journal Article

Loading…

571P Artificial intelligence-powered analysis of tumor lymphocytes infiltration: A translational analysis of AtezoTRIBE trial

by Carullo, M., Antoniotti, C., Ahn, C., Lee, T., Angerilli, V., Ambrosini, M., Rossini, D., Schietroma, F., Lonardi, S., Tamberi, S., Ghelardi, F., Seo, M., Righetto, A., Conca, V., Vetere, G., Shin, S., Ugolini, C., Ock, C-Y., M. fassan, Cremolini, C.
Published in Annals of oncology (01.10.2023)

Get full text

Journal Article

Loading…

SO-32 Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)

by Germani, M., Moretto, R., Ros, J., Intini, R., Ghelardi, F., Vetere, G., Toledo, R., Bergamo, F., Randon, G., Elez, E., Lonardi, S., Oldani, S., Giordano, M., Rossini, D., Bravo, W. Ferrari, Ricagno, G., Vignali, P., Ugolini, C., Fontanini, G., Cremolini, C.
Published in Annals of oncology (01.06.2023)

Get full text

Journal Article

Loading…

P-90 Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment

by Vetere, G., Germani, M., Bensi, M., Antoniotti, C., Lonardi, S., Passardi, A., Ghelardi, F., Calegari, M., Borelli, B., Santucci, S., Intini, R., Cristarella, E., Persano, M., Puccini, A., Lavacchi, D., Noto, L., Zichi, C., Giampieri, R., Salati, M., Cremolini, C.
Published in Annals of oncology (01.06.2023)

Get full text

Journal Article

Loading…

63P FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only (LL), right-sided and/or RAS or BRAF mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials

by Marmorino, F., Antoniotti, C., Meinert, F.M., Bergamo, F., Tonini, G., Rossini, D., Borelli, B., De Rosa, A., Allegrini, G., Stein, A., Moretto, R., Ronzoni, M., Zaniboni, A., Germani, M.M., Sperotto, S., Ongaro, E., Ghelardi, F., Masi, G., Schmoll, H.J.E-V., Cremolini, C.
Published in Annals of oncology (01.06.2024)

Get full text

Journal Article

Loading…

SO-22 Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study

by Marmorino, F., Piccinno, G., Rossini, D., Ghelardi, F., Murgioni, S., Salvatore, L., Nasca, V., Antoniotti, C., Daniel, F., Schietroma, F., Conca, V., Costa Silva, C. Alves, Tamburini, E., Tamberi, S., Passardi, A., Carullo, M., Antonuzzo, L., D'Onofrio, R., Zitvogel, L., Cremolini, C., Derosa, L.
Published in Annals of oncology (01.06.2023)

Get full text

Journal Article

Loading…

Treatment of patients with BRAF V600E -mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset

by Germani, M M, Vetere, G, Santamaria, F, Intini, R, Ghelardi, F, Bensi, M, Boccaccino, A, Minelli, A, Carullo, M, Ciracì, P, Passardi, A, Santucci, S, Giampieri, R, Persano, M, Fenocchio, E, Puccini, A, Lonardi, S, Pietrantonio, F, Salvatore, L, Cremolini, C
Published in ESMO open (01.04.2024)

Get full text

Journal Article

Loading…

Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset

by Germani, M.M., Vetere, G., Santamaria, F., Intini, R., Ghelardi, F., Bensi, M., Boccaccino, A., Minelli, A., Carullo, M., Ciracì, P., Passardi, A., Santucci, S., Giampieri, R., Persano, M., Fenocchio, E., Puccini, A., Lonardi, S., Pietrantonio, F., Salvatore, L., Cremolini, C.
Published in ESMO open (01.04.2024)

Get full text

Journal Article